Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial
Background and Objectives: Cutaneous leishmaniasis (CL) treatment is a challenging issue, although numerous modalities have been introduced as candidate treatment for CL yet only antimonial agents are commonly used to treat CL, a different form of amphotericin B is used to treat visceral form of leishmaniasis but the efficacy against CL is not high. There are a few reliable clinical trials on CL, the main reason is the nature of the disease which required a well design protocol to evaluate the efficacy of any candidate treatment against CL. In this study, a protocol was developed and used to evaluate a topical formulation of a nano-liposomal form of amphotericin B in addition to glucantime to treat CL caused by L. tropica.
Materials and Methods: This study is a phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of topical nano-liposomal amphotericin B (SinaAmpholeish 0.4%) in combination with intralesional injections of meglumine antimoniate in the treatment of ACL caused by L. tropica. Overall, 130 patients, aged 12-60 years, with a diagnosis of ACL caused by L. tropica are recruited and treated according to the protocol.
Results: A total of 130 patients with CL lesion will be recruited and double- blind randomly treated with received intralesional injections of Glucantime weekly or Glucantime plus SinaAmpholeish for 4 weeks.
Conclusion: The results of this study showed that the protocol works well and the treatment was tolerated by both groups of patients.
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7(5): e35671.
3. Postigo JA. Leishmaniasis in the World Health Organization Eastern Mediterranean region. Int J Antimicrob Agents 2010; 36 Suppl 1: S62-S65.
4. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61: 223-274.
5. Dowlati Y, Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol 1996;14: 513-517.
6. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute old world cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57(2): 335. e1-e29.
7. Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther 2014; 14: 1641-1649.
8. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One 2017; 12(9): e0184777.
9. Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ, Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32: 610-612.
10. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-248.
11. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol 2015; 6: 219.
12. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49 Suppl 1: 7-10.
13. Bellmann R, Cleary JD, Sterba J. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol 2009; 7: 1-8.
14. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-114.
15. Patel HM, Moghimi M (1998). Liposomes and the skin permeability barrier. In: Liposomes in drug delivery. Eds, G Gregoriadis, AT Florence, HM Patel. Routledge, 1st ed. London, UK, pp. 256.
16. Ghyczy M, Gareiss J, Kovats T, Liposomes from vegetable phosphatidylcholine: their production and effects on the skin. Cosmet Toilet 1994; 109: 75-80.
17. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M, Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994; 83: 1189-1203.
18. Inventors: Jaafari MR, Khamesipour A. Assignee: Exir Nano Sina Company, Tehran (IR). Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same. United States, Patent Application Publication. US 2015/0147382 A1.
19. Eskandari SE, Firooz A, Nassiri-Kashani M, Jaafari MR, Javadi A, Miramin-Mohammadi A, et al. Safety evaluation of nano-liposomal formulation of amphotericin B (Sina Ampholeish) in animal model as a candidate for treatment of cutaneous leishmaniasis. J Arthropod Borne Dis 2018; 12: 269-275.
20. Eskandari SE, Firooz A, Nassiri-Kashani M, Jaafari MR, Javadi A, Miramin Mohammadi A, et al. Safety evaluation of topical application of nano-liposomal form of amphotericin B (SinaAmpholeish) on healthy volunteers: phase I clinical trial. Iran J Parasitol 2019; 14: 197-203.
21. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 2013; 7(3): e2130.
22. Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, et al. Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLoS Negl Trop Dis 2018; 12(1): e0006141.
|Issue||Vol 13 No 5 (2021)|
|Treatment; Leishmaniasis; Cutaneous; Anthroponotic; Clinical trial; Protocol|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|